Assembly Bio Slashes Net Loss, Secures $35M Gilead Licensing Fee, Extends Cash Runway to 2028
Summary
Assembly Biosciences reported significantly improved year-end 2025 financial results, including a reduced net loss of $6.1 million, down from $40.2 million in 2024. The company's cash position increased to $248.1 million, extending its cash runway into 2028. A key highlight was the successful licensing of its helicase-primase inhibitor program for recurrent genital herpes to Gilead Sciences, which included a net $35 million option fee. This financial and pipeline update is highly material for Assembly Biosciences, validating its scientific platform and providing substantial capital for future development. Investors will be watching for the company's decision by mid-2026 on whether to opt into a 40% U.S. cost-profit share for the herpesvirus HPI program and the anticipated Phase 2 initiation for ABI-6250 by year-end 2026.
At the time of this announcement, ASMB was trading at $28.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $435.1M. The 52-week trading range was $7.75 to $39.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.